Review of past and present clinical cases with a view to future treatment options

Javier Martín-Broto, Peter Reichardt, Silvia Stacchiotti, Jean Yves Blay

Research output: Contribution to journalArticlepeer-review

Abstract

In the 10 years that have elapsed since trabectedin was first granted approval in Europe for treatment of advanced soft tissue sarcoma (STS), other cytotoxic agents and targeted therapies have been approved and numerous randomized controlled trials have been completed or are underway. As an academic exercise and positive proof of the advances in STS management that have occurred during the past decade, it is interesting to compare current and future treatment approaches. In this review, present and future treatment approaches are examined by case study for three STS subtypes: uterine leiomyosarcoma, abdominal dedifferentiated liposarcoma and malignant solitary fibrous tumor.

Original languageEnglish
Pages (from-to)11-28
Number of pages18
JournalFuture Oncology
Volume13
Issue number13s
DOIs
Publication statusPublished - Jun 1 2017

Keywords

  • dedifferentiated liposarcoma
  • solitary fibrous tumor
  • trabectedin
  • uterine leiomyosarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Review of past and present clinical cases with a view to future treatment options'. Together they form a unique fingerprint.

Cite this